TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20065132

Group type: EXPERIMENTAL
Intervention: High-intensity aerobic exercise (75% to 85% of heart rate reserve for 45 to 60 min/d, 4 d/wk for 6 months)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Stretching control group (maintained heart rate at or below 50% of heart rate reserve for the same schedule)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: High-intensity aerobic exercise
Number of subjects: 33
Study: 22874106

Group type: EXPERIMENTAL
Intervention: Ferumoxytol (two 510 mg i.v. injections within 5 ± 3 days)
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Number of subjects: 608

Group type: COMPARATOR
Intervention: Oral iron
Number of subjects: 608
Study: 16201069

Group type: EXPERIMENTAL
Intervention: Nateglinide (270mg/day before each meal for 20 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-treated control group
Number of subjects: 10
Study: 12598441

Group type: EXPERIMENTAL
Intervention: NSAID ophthalmic solution (bromfenac sodium hydrate) co-administered twice daily for 2 weeks
Number of subjects: 13

Group type: COMPARATOR
Intervention: Latanoprost ophthalmic solution administered once daily
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Withdrawal of bromfenac sodium hydrate ophthalmic solution
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Re-administration of bromfenac sodium ophthalmic solution
Number of subjects: 13
Study: 10378127

Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 78
Study: 8655705

Group type: EXPERIMENTAL
Intervention: Detection of abnormal expression of CD44 gene products in exfoliated cells from patients with colorectal carcinoma.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Detection of retention of intron 9 in CD44 mRNA transcripts in washings from carcinoma specimens.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Examination of solid tissue samples from patients with colorectal carcinoma.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Detection of low level expression of CD44 exons in tissue from inflammatory lesions.
Number of subjects: 27
Study: 1856922

Group type: EXPERIMENTAL
Intervention: Tailored and valved (modified) ileal ureter
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard operation
Number of subjects: 50
Study: 6347277

Group type: EXPERIMENTAL
Intervention: Tamoxifen (30 mg daily for 1 year)
Number of subjects: 720

Group type: COMPARATOR
Intervention: No further therapy (Control)
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 720

Group type: COMPARATOR
Intervention: Tamoxifen and No further therapy (both)
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: PgR negative patients
Number of subjects: 720
Study: 30475959

Group type: EXPERIMENTAL
Intervention: Higher-protein group (>0.80 g · kg‐1 · d‐1)
Number of subjects: 729

Group type: COMPARATOR
Intervention: Lower-protein group (≤0.80 g · kg‐1 · d‐1)
Number of subjects: 729

Group type: EXPERIMENTAL
Intervention: Higher-protein group
Number of subjects: 729

Group type: COMPARATOR
Intervention: Lower-protein group
Number of subjects: 729
Study: 28816912

Group type: EXPERIMENTAL
Intervention: 3-part distance-learning, quality improvement intervention (web-based education, collaborative consultation with ADHD experts, performance feedback reports/calls)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 105
Study: 26654738

Group type: EXPERIMENTAL
Intervention: Polyhexamethylene biguanide (PHMB)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Ringer's lactate solution (RLS)
Number of subjects: 31
Study: 24050808

Group type: EXPERIMENTAL
Intervention: Caseload midwifery care
Number of subjects: 1748

Group type: COMPARATOR
Intervention: Standard maternity care
Number of subjects: 1748
Study: 21935814

Group type: EXPERIMENTAL
Intervention: Flunarizine (10 mg, 2 capsules of 5 mg each)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (2 capsules)
Number of subjects: 30
Study: 18174769

Group type: EXPERIMENTAL
Intervention: Morning hypertension (MEdif >/=15 mm Hg, MEave >/=135 mm Hg)
Number of subjects: 611

Group type: COMPARATOR
Intervention: Well-controlled blood pressure (MEdif <15 mm Hg, MEave <135 mm Hg)
Number of subjects: 611
Study: 17186724

Group type: EXPERIMENTAL
Intervention: Qianggan Capsule combined with Lamivudine
Number of subjects: 85

Group type: COMPARATOR
Intervention: Qianggan Capsule alone
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Both groups (QC and Lamivudine, QC alone)
Number of subjects: 85
Study: 12811626

Group type: EXPERIMENTAL
Intervention: Intermittent cyclical etidronate (ICE)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Total DPD by HPLC
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Free DPD by ELISA
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 94
Study: 10875616

Group type: EXPERIMENTAL
Intervention: gp120 vaccines
Number of subjects: 296

Group type: COMPARATOR
Intervention: SF-2/gp120
Number of subjects: 296
Study: 8864325

Group type: EXPERIMENTAL
Intervention: Reboxetine 0.5 mg, 1 mg, or 4 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg with alcohol (0.6 mg kg‐1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo with alcohol (0.6 mg kg‐1)
Number of subjects: 10
Study: 1497132

Group type: EXPERIMENTAL
Intervention: bupivacaine+buprenorphine (0.3 mg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: bupivacaine (without buprenorphine)
Number of subjects: 80

Group type: COMPARATOR
Intervention: control group (untreated parturients)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: bupivacaine (with or without buprenorphine)
Number of subjects: 80
Study: 6407433

Group type: EXPERIMENTAL
Intervention: Nitrate derivatives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Betablockers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31790015

Group type: EXPERIMENTAL
Intervention: Bitemporal tDCS (anodal stimulation over the temporal cortices, 2 mA for 20 minutes)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Bifrontal tDCS (anodal stimulation over the dorsolateral prefrontal cortices, 2 mA for 20 minutes)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 17
Study: 30236904

Group type: EXPERIMENTAL
Intervention: Home-based biofeedback therapy (20 min self-training sessions twice per day using a self-inserted probe for visual feedback)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Office-based biofeedback therapy (therapist-guided pelvic floor training for six sessions over 3 months)
Number of subjects: 100
Study: 26611663

Group type: EXPERIMENTAL
Intervention: Teens.Connect (Internet psychoeducational program)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Planet D (open-access diabetes website)
Number of subjects: 124
Study: 24691901

Group type: EXPERIMENTAL
Intervention: Nitazoxanide 675 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Nitazoxanide 2700 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 22421463

Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) supplementation (maltodextrin solution)
Number of subjects: 24
Study: 21250571

Group type: EXPERIMENTAL
Intervention: Experimental polishing kit (EXL-695)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Enhance‐Pogo polishing kit
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sof‐Lex polishing kit
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Astropol polishing kit
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 24
Study: 17543894

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 15919688

Group type: EXPERIMENTAL
Intervention: Vitamin E-bonded dialyzer
Number of subjects: 7

Group type: COMPARATOR
Intervention: Non-vitamin E-bonded dialyzer
Number of subjects: 7
Study: 12133656

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 598

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 598
Study: 10425048

Group type: EXPERIMENTAL
Intervention: DNA image cytometry
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control cells (lymphocytes and neutrophilic granulocytes)
Number of subjects: 54
Study: 7758234

Group type: EXPERIMENTAL
Intervention: Octreotide (100 micrograms subcutaneous injections, 3 injections over one day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (octreotide vehicle, 3 injections over one day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 10
Study: 2271804

Group type: EXPERIMENTAL
Intervention: Humorous stimulus
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Overt crying
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Inhibition of weeping
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sad stimulus
Number of subjects: 39
Study: 6163281

Group type: EXPERIMENTAL
Intervention: Zinc sulphate 600 mg daily
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 30782701

Group type: EXPERIMENTAL
Intervention: 60 hours CIMT + full-time cast
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: 60 hours CIMT + part-time splint
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: 30 hours CIMT + full-time cast
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: 30 hours CIMT + part-time splint
Number of subjects: 135

Group type: COMPARATOR
Intervention: Usual and Customary Treatment (UCT)
Number of subjects: 135
Study: 28087133

Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 1470

Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 1470
Study: 25480678

Group type: EXPERIMENTAL
Intervention: HydroCoil Embolic System (HES)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Bare platinum coils (BPC)
Number of subjects: 96
Study: 24049109

Group type: EXPERIMENTAL
Intervention: 5 μg dmLT
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 25 μg dmLT
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 50 μg dmLT
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 100 μg dmLT
Number of subjects: 36
Study: 20606594

Group type: EXPERIMENTAL
Intervention: CHOICE
Number of subjects: 208

Group type: COMPARATOR
Intervention: Control
Number of subjects: 208
Study: 19667281

Group type: EXPERIMENTAL
Intervention: Efavirenz at 600 mg/day plus stavudine‐lamivudine
Number of subjects: 71
Study: 17561956

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Sustained-release carbamazepine (CBZ)
Number of subjects: 185
Study: 15333258

Group type: EXPERIMENTAL
Intervention: Urinary-derived Metrodin-HP
Number of subjects: 5

Group type: COMPARATOR
Intervention: Recombinant-derived Gonal F
Number of subjects: 5
Study: 11488378

Group type: EXPERIMENTAL
Intervention: leaky, competing accumulator model
Number of subjects: 0
Study: 10911490

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg) daily
Number of subjects: 25

Group type: COMPARATOR
Intervention: Fluoxetine (20 mg) every 3 days
Number of subjects: 25
Study: 8907211

Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estrogen replacement
Number of subjects: 0
Study: 1975819

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 364260

Group type: EXPERIMENTAL
Intervention: 40 mg of acetylsalicylic acid
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ascorbic acid (placebo)
Number of subjects: 12
Study: 31511290

Group type: EXPERIMENTAL
Intervention: Group-based online intervention for physical activity (10-week program delivered through a private Facebook group, including education on PA and diet, and provision of an activity tracker (Fitbit)).
Number of subjects: 100
Study: 27294812

Group type: EXPERIMENTAL
Intervention: 12-step facilitation therapy
Number of subjects: 0
Study: 25907712

Group type: EXPERIMENTAL
Intervention: Combined exercise program (resistance, endurance, and balance training) for 12 weeks, 1 hour per day, 3 days per week
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 29
Study: 23649091

Group type: EXPERIMENTAL
Intervention: Anthrax Vaccine Adsorbed (AVA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HLA-A homozygosity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HLA-DQA1 homozygosity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HLA-DQB1 homozygosity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Homozygosity at ≥ 4 HLA loci
Number of subjects: 0
Study: 21499123

Group type: EXPERIMENTAL
Intervention: Low-Dose IFN‐α-2a treatment
Number of subjects: 850
Study: 20082927

Group type: EXPERIMENTAL
Intervention: Moderate diet-induced weight loss
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Partial weight regain
Number of subjects: 60
Study: 16723584

Group type: EXPERIMENTAL
Intervention: Brecanavir (BCV) 300 mg coadministered with 100 mg ritonavir (RTV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brecanavir (BCV) without RTV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brecanavir (BCV) (doses ranging from 25 mg to 800 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12837664

Group type: EXPERIMENTAL
Intervention: PI-HAART
Number of subjects: 93

Group type: COMPARATOR
Intervention: PI-naive
Number of subjects: 93

Group type: COMPARATOR
Intervention: HIV-seronegative controls
Number of subjects: 93
Study: 10571715

Group type: EXPERIMENTAL
Intervention: AHCPR guidelines with additional education, spirometry, and carbon monoxide measurements
Number of subjects: 205

Group type: COMPARATOR
Intervention: AHCPR guidelines without additional education
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Number of subjects: 205

Group type: COMPARATOR
Intervention: Historical data
Number of subjects: 205
Study: 8546739

Group type: COMPARATOR
Intervention: Polymer-based saliva substitutes (3 types)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Polyacrylic acid-based saliva substitutes
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Low-viscoelastic saliva substitutes
Number of subjects: 43
Study: 1712270

Group type: EXPERIMENTAL
Intervention: Cilazapril 2.5 mg
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Cilazapril 5 mg
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study: 6406459

Group type: EXPERIMENTAL
Intervention: Bupropion hydrochloride (100, 200, and 400 mg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: d‐amphetamine sulfate (15 and 30 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 3873175

Group type: EXPERIMENTAL
Intervention: Dexamethasone antenatal therapy
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 31710096

Group type: EXPERIMENTAL
Intervention: School-based interventions (prohibition of sugary snack consumption, teacher supervised daily brushing using fluoridated toothpaste, oral health education)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Active control (tooth brushing and oral health education)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Negative control (only oral health education)
Number of subjects: 420
Study: 30053283

Group type: EXPERIMENTAL
Intervention: Canola oil diet; 60 g of treatment oil per day for 4 weeks; increased cholesterol efflux capacity by 39% (P < 0.05) compared to baseline.
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: High oleic acid-canola oil diet; 60 g of treatment oil per day for 4 weeks; increased cholesterol efflux capacity by 34% (P < 0.05) compared to baseline.
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: DHA-enriched high oleic acid-canola oil diet; 60 g of treatment oil per day for 4 weeks; increased cholesterol efflux capacity by 55% (P < 0.05) compared to baseline.
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Corn oil and safflower oil blend diet; 60 g of treatment oil per day for 4 weeks; increased cholesterol efflux capacity by 49% (P < 0.05) compared to baseline.
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Flax oil and safflower oil blend diet; 60 g of treatment oil per day for 4 weeks; increased cholesterol efflux capacity by 51% (P < 0.05) compared to baseline.
Number of subjects: 101
Study: 27271136

Group type: EXPERIMENTAL
Intervention: Eight-week meditation program
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study: 24942012

Group type: EXPERIMENTAL
Intervention: Bioresorbable polymeric scaffolds
Number of subjects: 303
Study: 22410646

Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV)
Number of subjects: 1940

Group type: COMPARATOR
Intervention: Trivalent inactivated influenza vaccine (TIV)
Number of subjects: 1940
Study: 20511294

Group type: EXPERIMENTAL
Intervention: ABI < 0.50
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: ABI 0.50-0.70
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: ABI 0.71-0.95
Number of subjects: 156
Study: 18641036

Group type: EXPERIMENTAL
Intervention: Generic formulation of Triomune 40 (stavudine 40 mg, lamivudine 150 mg, nevirapine 200 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Branded formulation of Triomune 40 (stavudine 40 mg, lamivudine 150 mg, nevirapine 200 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Generic formulation of Triomune 40
Number of subjects: 16

Group type: COMPARATOR
Intervention: Branded formulation of Triomune 40
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 16
Study: 15607260

Group type: EXPERIMENTAL
Intervention: Test product (T)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Reference product (R)
Number of subjects: 28
Study: 14569644

Group type: EXPERIMENTAL
Intervention: 7 1/2 hour educational program for staff
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no educational program)
Number of subjects: 40
Study: 10536549

Group type: EXPERIMENTAL
Intervention: morphine plus diclofenac 1 mg kg‐1
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: morphine plus paracetamol 15-20 mg kg‐1
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: morphine plus a combination of both diclofenac and paracetamol
Number of subjects: 80

Group type: COMPARATOR
Intervention: PCA morphine alone
Number of subjects: 80
Study: 8923399

Group type: EXPERIMENTAL
Intervention: Ultrasound examination (active intensity of 2.0 W/cm2)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Bone scintiscan (reference standard)
Number of subjects: 78
Study: 1681264

Group type: EXPERIMENTAL
Intervention: Vegetarian diet after fasting
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (ordinary diet)
Number of subjects: 53
Study: 31482947

Group type: EXPERIMENTAL
Intervention: Saltier bread samples (no specific dosage mentioned)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Bread with oregano seasoning (no specific dosage mentioned)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Lowest salt concentration sample
Number of subjects: 118
Study: 30063372

Group type: EXPERIMENTAL
Intervention: Winter season
Number of subjects: 1175

Group type: EXPERIMENTAL
Intervention: Spring season
Number of subjects: 1175

Group type: EXPERIMENTAL
Intervention: Summer season
Number of subjects: 1175

Group type: EXPERIMENTAL
Intervention: Fall season
Number of subjects: 1175

Group type: EXPERIMENTAL
Intervention: Southeast and West regions
Number of subjects: 1175
Study: 27592725

Group type: EXPERIMENTAL
Intervention: Narrow bed (emergency stretcher)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wide bed (standard hospital bed)
Number of subjects: 0
Study: 25744418

Group type: EXPERIMENTAL
Intervention: Dairy-consumption group (400 g/d for 24 wk)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (dietary intervention focused on weight control)
Number of subjects: 200
Study: 22247420

Group type: EXPERIMENTAL
Intervention: High-risk genetic results
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Low-risk genetic results
Number of subjects: 175
Study: 19188391

Group type: EXPERIMENTAL
Intervention: Doripenem (500 mg every 8 hours)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Levofloxacin (250 mg every 24 hours)
Number of subjects: 24
Study: 18221624

Group type: EXPERIMENTAL
Intervention: Treatment step 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment step 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment step 3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment step 4
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increasing treatment steps
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up in remission
Number of subjects: 0
Study: 15888130

Group type: EXPERIMENTAL
Intervention: Vaseline oil pretreatment with UVB TL01 phototherapy
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no vaseline oil pretreatment)
Number of subjects: 15
Study: 12060043

Group type: EXPERIMENTAL
Intervention: pantoprazole 40 mg once daily
Number of subjects: 256

Group type: COMPARATOR
Intervention: ranitidine 150 mg twice daily
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: pantoprazole
Number of subjects: 256
Study: 10474492

Group type: EXPERIMENTAL
Intervention: Computer assisted analysis of lung area on chest radiograph
Number of subjects: 50

Group type: COMPARATOR
Intervention: Functional residual capacity (FRC) measurement
Number of subjects: 50
Study: 9139274

Group type: EXPERIMENTAL
Intervention: IL‐6 urinary excretion in IDDM patients with albuminuria (mean = 7.43 +/‐ 8.29 pg/mg creatinine)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: TGF‐beta urinary excretion in IDDM patients with albuminuria (mean = 42.0 +/‐ 30.0 pg/mg creatinine)
Number of subjects: 12
Study: 1860294

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine mouthrinse
Number of subjects: 14

Group type: COMPARATOR
Intervention: 0.1% chlorhexidine mouthrinse
Number of subjects: 14
Study: 6662638

Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Number of subjects: 124

Group type: COMPARATOR
Intervention: Heparin-DHE
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Injection in the upper arm
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Subcutaneous thrombin administration
Number of subjects: 124